BCL10 and diffuse large B-cell lymphoma: Consistent with this result, we found that a subset of GCB-DLBCL cell lines (e.g., SU-DHL4, SU-DHL6 and Karpas-422 cells) responded to BCL10 inhibitors (Figure 5A-B) but not MALT1 inhibitors 42, suggesting a broader antitumor spectrum for BCL10 inhibition than MALT1 inhibition.